Company intelligence / Profile preview

Mainz BioMed

Mainz, Rhineland-Palatinate, Germanymainzbiomed.com ↗

Ownership: Private
Employees: ~100
Development stage: Commercial

Overview

Mainz BioMed develops molecular genetic diagnostic solutions focused on the early detection of colorectal and pancreatic cancers. Its lead product, ColoAlert®, a CE-marked stool DNA test integrating proprietary mRNA biomarkers and an AI-driven algorithm with FIT testing, has demonstrated high sensitivity/specificity in feasibility studies. The eAArly DETECT 2 clinical study aims to validate these results over ~2,000 patients by Q4'25 to support FDA approval. The company also holds licenses to novel blood-based mRNA markers targeting pancreatic cancer.

Therapeutic areas: Oncology
Modalities: Molecular assay (PCR-based)mRNA biomarker testCompanion diagnostic (in development)Blood-based biomarker test (in development)AI-developed algorithm for diagnosticsFecal immunochemical test integration
Industry: Molecular Diagnostics

Drug pipeline

2 assets

ColoAlert

Commercial

Indications: Colorectal cancer

1 more asset in the full pipeline.

Request access →

Partnerships

Liquid Biosciences (license agreement for novel mRNA markers/pancreatic CA)labor team w ag (diagnostic laboratory partnership)

Beyond the preview

Go deeper on Mainz BioMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mainz BioMed.

Explore the full profile